Phase I evaluation of beta-2'-deoxythioguanosine in pediatric patients with leukemia

Thirty-one pediatric patients with acute leukemia who had relapsed on either 6-mercaptopurine or 6-thioguanine were treated with beta-2'-deoxythioguanosine, which was administered as an iv infusion every 12 hours for three or six doses every 2 weeks. Severe nausea and vomiting and urate nephrop...

Full description

Saved in:
Bibliographic Details
Published inCancer treatment reports Vol. 69; no. 6; p. 699
Main Authors Higgins, G R, Jamin, D C, Shore, N A, Momparler, R, Hartman, G, Siegel, S E
Format Journal Article
LanguageEnglish
Published United States 01.01.1985
Subjects
Acute Disease
Acute Kidney Injury - chemically induced
Child
Deoxyguanosine - analogs & derivatives
Deoxyguanosine - therapeutic use
Deoxyguanosine - toxicity
Drug Evaluation
Humans
Leukemia - drug therapy
Leukemia, Lymphoid - drug therapy
Nausea - chemically induced
Thionucleosides - therapeutic use
Thionucleosides - toxicity
Uric Acid - urine
Vomiting - chemically induced
Online AccessGet more information

Cover

More Information
Summary:Thirty-one pediatric patients with acute leukemia who had relapsed on either 6-mercaptopurine or 6-thioguanine were treated with beta-2'-deoxythioguanosine, which was administered as an iv infusion every 12 hours for three or six doses every 2 weeks. Severe nausea and vomiting and urate nephropathy were the dose-limiting toxic effects. Therapeutic responses occurred in four of 24 children with acute lymphocytic leukemia and in two of seven with acute nonlymphoblastic leukemia.
ISSN:0361-5960